FierceBiotech

About a month after Pfizer CEO Albert Bourla told investors that the Big Pharma’s pipeline pruning was mostly done, the company has scrapped a phase 1 antibody-drug conjugate that was being tested in solid tumors. $PFE fiercebiotech.com/biotech/pfizer…

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. $ALDX fiercebiotech.com/biotech/fda-re…

Roche has inked a deal with Nvidia to bolster the pharma’s “hybrid-cloud AI factory” designed to accelerate development for new therapeutics and diagnostics. fiercebiotech.com/biotech/roche-…

The layoffs come as the FDA warns that it might not consider Inovio's rare disease candidate for accelerated approval after all. $INO fiercebiotech.com/biotech/inovio…

Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price. $NVO fiercebiotech.com/biotech/novo-h…

Evotec has escalated its already substantial reorganization, plotting an additional round of 800 layoffs and multiple site closures. fiercebiotech.com/biotech/evotec…

Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years. fiercebiotech.com/biotech/molecu…

Less than a week after Roche pledged a hefty investment in the South Korean biopharma industry, Eli Lilly is following suit with a $500 million, five-year pact of its own. fiercebiotech.com/biotech/lilly-…

AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in one dose cohort. fiercebiotech.com/biotech/abbvie… $ABBV

FDA’s Vinay Prasad to step down at the end of April fiercebiotech.com/biotech/fdas-v…

“... uniQure is performing a distorted or manipulated comparison in the mind of FDA,” an agency official said yesterday in a media call. “The recent statements made by anonymous FDA sources to the press have been highly irregular, unprecedented, and are incomplete or entirely incorrect,” uniQure told Fierce afterwards. “We do not believe they reflect a fair and faithful reading of the documents we have submitted or those we have received from the agency.” $QURE fiercebiotech.com/biotech/senior…

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. fiercebiotech.com/biotech/alltrn…

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma has secured $400 million to fuel the drug’s development. fiercebiotech.com/biotech/teva-b…

Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. $IRON fiercebiotech.com/biotech/disc-l…

French biotech OSE is downsizing its pipeline after its Boehringer-partnered SIRPα antagonist failed to show efficacy in a phase 2 MASH study. fiercebiotech.com/biotech/boehri…

2025’s biggest biotech money raisers were Isomorphic Labs and Kailera Therapeutics, with both companies securing $600 million financing rounds. Find out who else made the list here ⬇️ fiercebiotech.com/biotech/biotec…

Shares of uniQure plummeted more than 40% in premarket trading after confirming that the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for Huntington’s disease. $QURE fiercebiotech.com/biotech/uniqur…

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant regulatory red tape stands in the way of progress, two leaders in the field told Fierce. fiercebiotech.com/research/car-t…

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, providing further validation of the Big Pharma's $800 million bet on the candidate. $BMY fiercebiotech.com/biotech/bristo…

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar of his strategy, he wasn’t lying. The British pharma has just announced its second biotech acquisition in as many months, proving the company is willing to splash the cash for desirable assets. $GSK fiercebiotech.com/biotech/gsk-pa…